$407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients$

407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

Bibliographic Details
Main Authors:	David Gilham, Caroline Lonez, Anne Flament, Frédéric Lehmann, Erik Alcantar-Orozco, Emilie Cerf, Charles Morris
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

Similar Items